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Background: For men on active surveillance for prostate cancer, biomarkers may improve 
prediction of reclassification to higher grade or volume cancer. This study examined the 
association of urinary PCA3 and TMPRSS2:ERG (T2:ERG) with biopsy-based reclassification.
Methods: Urine was collected at baseline, 6, 12, and 24 months in the multi-institutional Canary 
Prostate Active Surveillance Study (PASS), and PCA3 and T2:ERG levels were quantitated. 
Reclassification was an increase in Gleason score or ratio of biopsy cores with cancer to ≥34%. 
The association of biomarker scores, adjusted for common clinical variables, with short-term and 
long-term reclassification was evaluated. Discriminatory capacity of models with clinical variables 
alone or with biomarkers was assessed using receiver operating characteristic (ROC) curves and 
decision curve analysis (DCA).
Results: 782 men contributed 2,069 urine specimens. After adjusting for PSA, prostate size and 
ratio of biopsy cores with cancer, PCA3 but not T2:ERG was associated with short-term 
reclassification at the first surveillance biopsy (OR=1.3; 95% CI 1.0–1.7, p=0.02). The addition of 
PCA3 to a model with clinical variables improved area under the curve from 0.743 to 0.753 and 
increased net benefit minimally. After adjusting for clinical variables, neither marker, nor marker 
kinetics, was associated with time to reclassification in subsequent biopsies.
Conclusions: PCA3 but not T2:ERG was associated with cancer reclassification in the first 
surveillance biopsy, but has negligible improvement over clinical variables alone in ROC or DCA 
analyses. Neither marker was associated with reclassification in subsequent biopsies.
Keywords
PCA3; TMPRSS2:ERG; biomarkers; prostate cancer; active surveillance
INTRODUCTION
Active surveillance (AS) is a management strategy for many clinically localized prostate 
cancers that allows men to delay or be spared the potential morbidities of treatment.1 
Cancers that appear relatively low-risk at diagnosis are monitored, typically with regular 
clinical exams, serial prostate-specific antigen (PSA) measurements, and repeat prostate 
biopsies. However, uncertainty about the possibility of occult aggressive cancer is one factor 
tempering widespread adoption of AS.2,3 Furthermore, optimal surveillance schedules and 
triggers for intervention have not yet been established,1 resulting in substantial variation in 
the practice of AS.4 Biomarkers that are collected non-invasively and that improve the 
prediction of aggressive behavior could improve the utilization of AS and inform decisions 
about the intensity of surveillance regimens.
During AS, treatment is usually recommended when higher grade or volume disease is 
found by biopsy. Biomarkers that detect the presence of occult high grade or high volume 
disease or that predict future reclassification to high grade or volume cancer could have 
substantial clinical utility. Importantly, biomarkers should incrementally improve upon 
models that are based on commonly available clinical variables.
In the present study, we evaluated PCA3 and TMPRSS2:ERG (T2:ERG) mRNA, which are 
two prostate-specific biomarkers present in urine,5,6 for their potential utility in AS. Clinical 
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grade assays have been developed for both of these biomarkers,6,7 and both have 
demonstrated ability to improve on PSA and clinical factors in detection of prostate cancer.
6,8
 Here, we evaluated whether PCA3 and T2:ERG assayed at multiple time-points during 
AS associated with reclassification to high grade or high volume cancer. We assessed if 
these biomarkers were associated with reclassification at the next surveillance biopsy. We 
also evaluated if PCA3 and T2:ERG collected early in or serially during AS associated with 
time to reclassification in later surveillance biopsies.
MATERIALS AND METHODS
Study Population
The multi-center Canary Prostate Active Surveillance Study (PASS) enrolls men diagnosed 
with clinically localized prostate cancer who chose to use AS to manage their cancer. Men 
provide informed consent under institutional review board supervision at nine centers 
(clinicaltrials.gov NCT00756665). Under the PASS protocol, PSA is measured every 3 
months, clinic visits occur every 6 months, and ultrasound-guided biopsies are performed 6–
12 months and 24 months after diagnosis, and then every 2 years. Specimens, including 
post-DRE urine, are collected at study entry and every 6 months. Follow-up data was 
collected September 2008 to February 2017. Men were included in the analysis if they had 
Gleason score ≤3+4 and <34% ratio of biopsy cores with cancer to total cores collected prior 
to urine collection. Men were excluded if they enrolled in PASS >5 years after diagnosis or 
if they had no on-study biopsy for endpoint determination.
Biomarker Collection
Urine samples were collected, assays performed, and biomarker scores calculated as 
described previously.9 For this analysis, all urine specimens from study entry, 6, 12, and 24 
month visits that were available in July 2014 were assayed.
Statistical Models for Reclassification
Reclassification was defined as an increase in primary or secondary Gleason grade at biopsy 
and/or an increase in the biopsy cores with cancer to total cores collected (cores ratio) to 
≥34%.10 Several models of reclassification were considered, as depicted in the Study 
Schematic (Figure 1).
Modeling short-term biopsy reclassification (Figure 1, panels A and B)
The association between urine biomarkers collected immediately prior to a biopsy and 
reclassification at the biopsy was modeled using logistic regression. The analysis was 
stratified by the first surveillance biopsy (sBx1, sometimes called confirmatory biopsy; 
Figure 1, Scenario A; n=552) and subsequent surveillance biopsies (Figure 1, Scenario B; 
n=446).
Modeling time to reclassification with longitudinal biomarkers (Figure 1, panel C)
The association between PCA3 or T2:ERG and the time to biopsy reclassification was 
modeled using a partly conditional Cox proportional hazards (PH) model.11 Participants 
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were excluded from this analysis if they reclassified at the sBx1. Each participant had the 
first urine biomarkers assayed after diagnosis and prior to sBx1 and had up to 3 additional 
urine samples collected up to 2 years after the first. The first urine biomarker sample along 
with the urine biomarker kinetics at each observation time were covariates in the partly 
conditional Cox model (Figure 1, panel C; n=405). Participants without reclassification were 
censored at date of last study contact, treatment, or 2 years after their last biopsy, whichever 
came first.
Urine biomarker kinetics were calculated based on a linear mixed effect model (LMEM), in 
which the natural log of the urine biomarkers was modeled as a linear function of time since 
diagnosis, with a random intercept indicating the individual-specific ln(urine biomarker) at 
diagnosis, and a random slope reflecting individual-specific rate of change over time. A 
PCA3 or T2:ERG kinetics (PCA3k or T2:ERGk) value for each participant based on the first 
urine sample up to an observation time was then derived based on the best linear unbiased 
predictor (BLUP) estimator from the LMEM.11 Intra-class correlation (ICC) was calculated 
to determine the proportion of total variability in biomarker scores explained by between-
participant variability.
For statistical models, the natural log (ln) of the urine biomarkers was calculated as 
ln(PCA3) and, due to possible values of 0 in T2:ERG, ln(T2:ERG + 1). We also adjusted for, 
as appropriate, most recent ln(PSA), ln[time since diagnosis (in years)], ln(prostate size), 
ln[maximum ratio of positive to total biopsy cores (cores ratio)], diagnostic Gleason score, 
number of prior biopsies, number of prior negative biopsies, cT-stage (T1a-c versus T2a-c), 
BMI (obese, overweight or normal), race (Caucasian, African American or other), ethnicity 
(Hispanic versus non-Hispanic/other), age at diagnosis, and family history of PCa. 
Insignificant clinical variables were backwards eliminated based on a p-value cutoff of 0.05. 
Robust variance estimators were used to account for multiple biopsies or urine specimens 
within participant, where appropriate (panels B and C).
Evaluation of clinical performance
If either PCA3 or T2:ERG was significant in a model, model performance was compared 
between a clinical model containing clinical and biopsy variables, and a model with the 
urine biomarkers added. Model performance was assessed with receiver operating 
characteristic (ROC) curves, area under the curve (AUC). Confidence intervals for model 
performance assessments were obtained by calculating 1000 bootstrap samples. Decision 
curve analysis (DCA) was used to report the clinical net benefit of each model compared to 
biopsy-all and biopsy-none strategies.12 All analyses were performed with SAS version 9.4 
and R version 3.4.1. Code is available upon request.
RESULTS
There were 782 participants included with a median follow-up of 4.9 years (IQR: 3.5, 6.5) 
among censored participants. Urine specimens were collected at six to twelve month 
increments such that 627 participants contributed at least 2 specimens, 448 contributed at 
least 3 specimens, and 209 contributed 4 specimens. There were 552 participants who had 
urine collected prior to the sBx1 (Figure 1). Median age was 63, PSA was 4.8, prostate size 
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was 40 cc, 94% were initially diagnosed with Gleason 3+3 cancer, and the median ratio of 
cores containing cancer to total biopsy cores (cores ratio) was 8.3% (Table 1). Results of 
each analysis depicted in Figure 1 are described below.
Analysis of reclassification at next biopsy
Of the 552 men with urine biomarkers assessed prior to the sBx1 (Figure 1, panel A), 130 
(24%) were reclassified at that biopsy. In a logistic regression model adjusted for PSA, cores 
ratio, and prostate size, PCA3 score was associated with reclassification in the sBx1 (OR = 
1.3; 95% CI: 1.0–1.7), and T2:ERG score was not (Table 2). A model in which the endpoint 
was only Gleason grade reclassification was similar (data not shown).
There was a small change in the AUC of a model for predicting reclassification at sBx1 
using clinical variables plus PCA3 versus a model with only clinical variables: 0.753 [95% 
CI 0.707–0.800] vs 0.743 [0.693–0.791] with and without PCA3 respectively (Figure 2). No 
improvement in AUC was found for a model including T2:ERG (Figure 2). Similar findings 
were observed in DCA (Figure 2). A model with clinical variables and PCA3 showed 
minimal increase in net benefit relative to a model with only clinical variables. All models 
with clinical variables showed an improvement to PCA3 alone, and all models showed an 
improvement to biopsy-all and biopsy-none strategies.
In the 446 men with urine biomarkers assessed prior to subsequent surveillance biopsies 
(Figure 1, panel B), 85 (19%) reclassified at the biopsy immediately following biomarker 
assessment (Supplemental Table 1). In a logistic regression model adjusted for clinical 
variables, neither PCA3 nor T2:ERG were associated with reclassification (OR = 1.01; 95% 
CI: 0.77, 1.32, p = 0.96, and OR = 1.12; 95% CI: 1.00, 1.27, p = 0.06, respectively; 
Supplemental Table 2).
Analysis of time to reclassification for longitudinal biomarkers
There were 405 participants included in the time-to-event analysis who had their first urine 
sample collected prior to the sBx1 and who did not reclassify at the sBx1 (Figure 1, panel 
C). With a median follow-up of 3.6 years from the first urine collection, 103 (25%) 
participants reclassified at any subsequent surveillance biopsy (Supplemental Table 3).
The annual percent change in PCA3 estimated by LMEM was 9.8 (95% CI 7.3–12.3, 
p<0.001). As determined by ICC, 85% of the observed variation in PCA3 was explained by 
between-participant variation, and 15% due to within-participant variation. The annual 
percent change in T2:ERG was 11.3 (95% CI 5.2–17.8, p<0.001), and 68% of the observed 
variation was explained by between-participant variation and 32% due to within-participant 
variation. Biomarker kinetics were calculated based on deriving a BLUP estimator from a 
LMEM.11 No significant differences in slopes were found between participants with 
reclassification versus those with no reclassification for either biomarker (Supplemental 
Figure 1).
In a Cox PH model adjusted for time since diagnosis, BMI, prostate size, cores ratio, 
biopsies since diagnosis (0 vs 1+), negative biopsies since diagnosis (0 vs 1+), and PSA, no 
significant association was found between baseline PCA3 or T2:ERG and reclassification 
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(HR for PCA3 = 1.16; 95% CI 0.86 – 1.57, p = 0.33, and HR for T2:ERG = 0.92; 95% CI = 
0.75 – 1.12, p = 0.40) or PCA3 or T2:ERG kinetics and reclassification (HR for 0.10 
increase in PCA3k = 0.96; 95% CI 0.44 – 2.09, p = 0.92, and HR for 0.10 increase in 
T2:ERGk = 1.56; 95% CI 0.73 – 3.34, p = 0.26) (Table 3).
DISCUSSION
Non-invasive assays for diagnosing or monitoring prostate cancer have the potential to aid 
treatment decisions and improve clinical outcomes. In this context, biomarkers assayed in 
urine represent an attractive approach and several urine-based assays have been developed. 
The Progensa PCA3 assay is a commercially available, analytically-validated diagnostic test 
that has been FDA approved to inform biopsy decision making in men with no known 
cancer and a previous negative biopsy. PCA3 is a prostate-specific non-coding mRNA and 
has been shown in many studies to improve predictive accuracy for cancer on initial biopsy,
7,8,13,14
 and to be correlated with more aggressive cancer at prostatectomy.15,16 At the time 
we initiated this work, the T2:ERG assay had been analytically validated6 and was being 
developed as a commercial assay. Thus, we hypothesized that both biomarker assays could 
improve management of patients using AS.
In this report from a multi-center contemporary AS cohort, we evaluated the association 
between urinary PCA3 and T2:ERG and biopsy reclassification using urine collected at 
multiple times during surveillance. The study was designed according to PRoBE criteria,17 
and analyses were tailored to help inform varying decisions made during AS. After adjusting 
for clinical and biopsy variables, we observed a significant association of PCA3 with 
reclassification at the sBx1, but only a modest improvement in AUC was found between a 
model with clinical variables only and a model with clinical variables plus PCA3. Similarly, 
in decision curve analysis minimal improvement in net benefit was observed when PCA3 
was added to models. We also found no association between either baseline PCA3 or 
T2:ERG and time to reclassification, and no association between changes in the biomarker 
scores over time and time to reclassification.
Our motivation for performing this study was that biomarkers that improve discrimination of 
indolent cancers and more aggressive tumors will not only support the practice of AS but 
also promote less intensive biopsy regimes. However, to optimize patient management and 
clinical utility, biomarkers should improve upon existing information. Multimodal risk 
assessment approaches that combine several sources of information into a risk score have 
been developed, such as the Prostate Cancer Prevention Trial (PCPT) Risk Calculator, which 
is used prior to a diagnosis of cancer to predict the risk of finding high grade cancer in the 
next biopsy,18 and PCA3 has been shown to improve the net benefit of the PCPT Risk 
Calculator.19 Several commercial biomarker panels employ such a multimodal strategy for 
predicting the risk of finding high grade cancer prior to a diagnosis of cancer, including the 
4Kscore20 and more recently the Select score.21 Because men who are candidates for AS 
have already been diagnosed with cancer and have available more clinical information than 
prior to diagnosis, risk models that include information from the index biopsy have been 
developed for the AS setting.22,23 These models utilize commonly available clinical 
variables and provide utility in risk prediction while on AS.
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Studies evaluating the use of PCA3 in AS have been limited and sample sizes have been 
small.24,25 In the current study, which is the largest study to date of PCA3 in men using AS, 
after adjustment for clinical variables available after cancer diagnosis, we found a significant 
association of PCA3 with reclassification at the sBx1 (adjusted OR = 1.3, p = 0.02), but not 
for subsequent biopsies (adjusted OR = 1.01, p = 0.96). Although we found no association 
between T2:ERG and biopsy reclassification, some studies have suggested improved 
performance when PCA3 and T2:ERG are used in combination26 or combined into a MiPS 
score for the initial diagnosis of PCa.27 We thus combined PCA3 and T2:ERG into a MIPS 
score, but found little or no improvement over PCA3 alone (data not shown).
In ROC curve analysis of models for predicting reclassification at sBx1, addition of PCA3 to 
a model that contained PSA, prostate size, and ratio of positive to total biopsy cores 
improved the AUC of the model very minimally. However, in a clinical setting, predictions 
are not being made over the full range of sensitivity and specificity. The likely use for a 
biomarker measured after a diagnosis of low-risk prostate cancer would be to “rule out” men 
who are at very low risk of harboring high grade or volume cancer, allowing them to delay 
having a biopsy. Thus we examined specificity at 95% sensitivity. The addition of PCA3 to a 
clinical model increased specificity at 95% sensitivity (0.156 vs 0.095), but the difference 
was not significant. Similarly, a slight improvement was seen in the net benefit of 
proceeding to biopsy for models including PCA3 at about 15% risk threshold, but at other 
risk thresholds addition of PCA3 to clinical variables made no improvement in the benefit of 
a decision to proceed to biopsy.
We also evaluated whether the urinary biomarkers, alone or in combination, improved upon 
clinical variables for prediction of time to future reclassification. Although PCA3 alone was 
associated with time to reclassification, when incorporated into a multivariable model 
neither PCA3 or T2:ERG were.
Using the same model, we evaluated if changes in PCA3 or T2:ERG scores measured over 
time (biomarker kinetics) were associated with reclassification. We used samples collected 
prior to the sBx1, and at 6 month intervals up to 2 years, and employed an analytic strategy 
that allowed the models to account for each individual biomarker measurement while 
utilizing information from the general trend across all participants and accommodating for 
random variability in the biomarkers. Although PCA3 increased over time, and both PCA3 
score and T2:ERG score were higher in men who reclassified than those who did not, there 
were no significant differences in the slopes of either biomarker over time for event versus 
non-event participants (Supplemental Figure 1), and we found no association between 
biomarker kinetics and reclassification. Our results are consistent with the one other 
longitudinal study of PCA3 in a smaller, more uniform risk cohort, suggesting that 
longitudinal PCA3 measurements do not add value over a single PCA3 measurement.25
We found a surprisingly large amount of variability in the longitudinal samples, in particular 
for T2:ERG. To assess the variation statistically, we used ICC, which can be interpreted as 
the proportion of total variability explained by between-participant variability. The variation 
in longitudinal measurements of PCA3 is very similar to that of PSA11 : for both PCA3 and 
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PSA, 15% of the variability can be attributed to random variability. However, 32% of the 
variability in T2:ERG was attributed to noise.
This study has limitations. Our design does not allow for us to address if the observed 
variability is due to biology, specimen collection methods, or assay performance. Second, 
although this is the largest study of urine biomarkers in AS published, the sample size is 
somewhat modest. However, while we expect that a larger sample size may reduce 
confidence intervals, we do not expect that it would result in different conclusions. Another 
limitation may be the reliability of our endpoint. Biopsy reclassification is imperfect in that 
it may reflect minimal changes in the tumor that may have little clinical importance. 
Nonetheless, our definition is consistent with those used in most AS cohorts, and 
importantly, drives treatment decisions in contemporary clinical practice. We did evaluate 
biomarker scores in only the 94% of men who were diagnosed with 3+3 disease and found 
no difference in results. Similarly, we evaluated biomarker scores in the 31 men who 
reclassified to 4+3 or higher at sBx1, and found no difference from the scores in the men 
who reclassified to 3+4 (data not shown).
In conclusion, we found that PCA3 was associated with reclassification at sBx1 in a 
multivariable model, but PCA3, or PCA3 and T2:ERG together, demonstrated minimal 
improvement to the clinical utility of a multivariable model. Neither PCA3 or T2:ERG was 
associated with time to reclassification at subsequent biopsies. Overall, we found that these 
markers add little or no improvement over clinical variables in predicting biopsy 
reclassification during AS.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Study design. For short-term prediction, analysis of the association of biomarkers with 
reclassification in the biopsy immediately following urine collection was performed using 
logistic regression for A.) 552 men with urine assayed prior to the first surveillance biopsy 
(sBx1) and B.) 446 men with urine assayed prior to subsequent surveillance biopsies. For 
longer-term prediction, the association of biomarkers with time to reclassification was 
examined in C.) 405 men with urine assayed prior to their sBx1 who did not reclassify at 
that biopsy; the first urine biomarker sample along with the urine biomarker kinetics at each 
observation time were considered as covariates in a partly conditional Cox model.
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Figure 2. 
Comparison of model performance from logistic regression model with grade and/or tumor 
volume reclassification at the first surveillance biopsy (sBx1). A) Receiver operating 
characteristic curves; dotted line corresponds to 95% sensitivity, B) .Decision curve analysis. 
Strategies for biopsying all men (grey) and no men (dark green) are also shown. The line 
with the highest net benefit at any particular risk threshold (x-axis) will yield the best 
clinical results.
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Table 1.
Description of participants with urine collected prior to the first surveillance biopsy (sBx1), distributed by 
outcome at sBx1.
Variable
All Participants n=552 Reclassifiers,
n=130
Non-Reclassifiers,
n=422
Median [IQR] Median [IQR] Median [IQR]
Age at Dx 63 [58, 67] 63 [58, 69] 63 [58, 67]
Race, n(%)
Caucasian American 500 (91) 115 (88) 385 (91)
African American 27 (5) 10 (8) 17 (4)
Other 25 (5) 5 (4) 20 (5)
Dx PSA 4.8 [3.8, 6.4] 5.1 [4.3, 6.3] 4.7 [3.6, 6.4]
Prostate size 40 [30, 55] 35 [25, 48] 42 [32, 60]
cT-stage, n(%)
T1a-T1c 508 (92) 118 (91) 390 (92)
T2a-T2c 44 (8) 12 (9) 32 (8)
Dx Gleason
3+3 521 (94) 120 (92) 401 (95)
3+4 31 (6) 10 (8) 21 (5)
Dx cores ratio 8.3 [8.3, 16.7] 16.7 [8.3, 24.5] 8.3 [8.3, 16.7]
BMI, n(%)
Normal 131 (24) 32 (25) 99 (23)
Overweight 283 (51) 63 (48) 220 (52)
Obese 138 (25) 35 (27) 103 (24)
PCA3 32 [18, 61] 39.5 [24, 89] 30 [16, 57]
T2:ERG 14 [2, 57] 27 [1, 82] 13 [2, 53]
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Table 2.
Logistic regression model results for grade and/or tumor volume reclassification in first surveillance biopsy (n 
= 552).
Variable*
Univariable Multivariable
OR (95% CI)^ p-value^ OR (95% CI)^ p-value^
PSA 1.5 (1.1, 2.0) 0.01 1.8 (1.3, 2.6) 0.001
Dx Cores Ratio 4.0 (2.6, 6.3) <.001 3.4 (2.1, 5.4) <.001
Prostate Size 0.3 (0.2, 0.5) <.001 0.3 (0.1, 0.4) <.001
PCA3 1.6 (1.2, 1.9) 0.0001 1.3 (1.0, 1.7) 0.02
T2:ERG 1.1 (1.0, 1.2) 0.21 1.0 (0.9, 1.2) 0.52
*
The natural log of all variables was used in modeling.
^Odds ratios, 95% confidence intervals and p-values from logistic regression models.
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Table 3.
Cox proportional hazards model results for grade and/or tumor volume reclassification using longitudinally 
collected samples (405 participants, 103 (25%) with event). PCA3k and T2:ERGk refer to the biomarker 
kinetics, respectively.
Variable
UnivariableŦ Multivariable
HR (95% CI)^ p-value^ HR (95% CI)^ p-value^
Time since Dx* 1.09 (0.95, 1.25) 0.22 1.01 (0.83, 1.23) 0.94
BMI
Obese vs Normal 1.28 (0.74, 2.22) 0.38 1.80 (1.04, 3.12) 0.04
Overweight vs Normal 0.92 (0.55, 1.52) 0.74 1.21 (0.74, 1.99) 0.44
Prostate Size* 0.49 (0.31, 0.77) 0.002 0.29 (0.17, 0.50) <.001
Max Prior Cores Ratio
  (10% increase) 1.68 (1.32, 2.13) <.001 1.30 (1.00, 1.69) 0.05
Prior Biopsy
  (1+ vs 0) 1.33 (1.05, 1.68) 0.02 2.09 (1.38, 3.14) <.001
Prior No Cancer Biopsy
  (1+ vs 0) 0.47 (0.30, 0.71) <.001 0.38 (0.23, 0.62) <.001
PSA* 1.66 (1.28, 2.17) <.001 2.18 (1.59, 2.99) <.001
PCA3* 1.57 (1.16, 2.12) 0.003 1.16 (0.86, 1.57) 0.33
PCA3k
  (0.10 unit increase) 1.62 (0.67, 3.91) 0.28 0.96 (0.44, 2.09) 0.92
T2:ERG* 0.98 (0.79, 1.21) 0.84 0.92 (0.75, 1.12) 0.40
T2:ERGk
  (0.10 unit increase) 1.40 (0.66, 2.95) 0.38 1.56 (0.73, 3.34) 0.26
*
The natural log of all variables was used in modeling.
Ŧ
PCA3 and PCA3k entered together; T2:ERG and T2:ERGk entered together.
^
Hazard ratios, 95% confidence intervals and p-values from Cox proportional hazards models.
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